R&D

Pipeline

HOME  >  R&D  >  Pipeline

The problem and market of cancer

The problem

1Relapse of tumor

2Development of drug resistance

3High cost of drug development and threat of failure

The market
Cancer stem cells (CSC) Targeting

NIBEC solution for cancer stem cell

  • Dual intracellular target: Intracellular protein (confidential)
  • Increase MET (mesenchymal to epithelial transition) and inhibit migration, adhesion, and metastasis
  • Effective for resistant cancer
  • Penetration through brain due to tissue penetration activity
  • Combination therapy with immune check point inhibitor due to IL-6 decreased by NIPEP-ACD-Tide
  • Effective for the reduction of side effect of immune check point inhibitor
  • Current status: preclinical study

NIPEP-ACD-Tide for the targeting of cancer stem cell

The peptide is easily internalized, and arrested the cancer stem cell marker. The result is the marked inhibition of tumor migration and tumor growth.